ES2052717T3 - Uso de derivados de indolona para la preparacion de medicamentos para el tratamiento de la enfermedad de parkinson. - Google Patents

Uso de derivados de indolona para la preparacion de medicamentos para el tratamiento de la enfermedad de parkinson.

Info

Publication number
ES2052717T3
ES2052717T3 ES88304555T ES88304555T ES2052717T3 ES 2052717 T3 ES2052717 T3 ES 2052717T3 ES 88304555 T ES88304555 T ES 88304555T ES 88304555 T ES88304555 T ES 88304555T ES 2052717 T3 ES2052717 T3 ES 2052717T3
Authority
ES
Spain
Prior art keywords
parkinson
preparation
disease
medicines
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88304555T
Other languages
English (en)
Spanish (es)
Inventor
David Andrew Arlwydd Owen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Smith Kline & French Laboratories Ltd
Original Assignee
Smith Kline & French Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10617727&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2052717(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smith Kline & French Laboratories Ltd filed Critical Smith Kline & French Laboratories Ltd
Application granted granted Critical
Publication of ES2052717T3 publication Critical patent/ES2052717T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
ES88304555T 1987-05-21 1988-05-19 Uso de derivados de indolona para la preparacion de medicamentos para el tratamiento de la enfermedad de parkinson. Expired - Lifetime ES2052717T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB878712073A GB8712073D0 (en) 1987-05-21 1987-05-21 Medicament

Publications (1)

Publication Number Publication Date
ES2052717T3 true ES2052717T3 (es) 1994-07-16

Family

ID=10617727

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88304555T Expired - Lifetime ES2052717T3 (es) 1987-05-21 1988-05-19 Uso de derivados de indolona para la preparacion de medicamentos para el tratamiento de la enfermedad de parkinson.

Country Status (21)

Country Link
US (2) US4824860A (enExample)
EP (1) EP0299602B1 (enExample)
JP (1) JPH062672B2 (enExample)
AT (1) ATE83659T1 (enExample)
AU (1) AU599792B2 (enExample)
CA (1) CA1305421C (enExample)
DE (1) DE3876877T2 (enExample)
DK (1) DK169609B1 (enExample)
ES (1) ES2052717T3 (enExample)
GB (1) GB8712073D0 (enExample)
GR (1) GR3007251T3 (enExample)
HK (1) HK1000913A1 (enExample)
HU (1) HU201871B (enExample)
IE (1) IE63511B1 (enExample)
LU (1) LU90098I2 (enExample)
MX (1) MX9203543A (enExample)
NL (1) NL970006I2 (enExample)
NZ (1) NZ224709A (enExample)
PH (1) PH23867A (enExample)
PT (1) PT87542B (enExample)
ZA (1) ZA883602B (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9008605D0 (en) * 1990-04-17 1990-06-13 Smith Kline French Lab Process
GB9015095D0 (en) * 1990-07-09 1990-08-29 Smith Kline French Lab Therapeutic method
JPH07506823A (ja) * 1992-05-18 1995-07-27 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 記憶障害，性的機能不全およびパーキンソン氏病の治療のためのインドロン誘導体の使用
GB9300309D0 (en) * 1993-01-08 1993-03-03 Smithkline Beecham Plc Process
GB9511366D0 (en) * 1995-06-06 1995-08-02 Smithkline Beecham Plc Novel formulations
GB9517062D0 (en) * 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
US5807570A (en) * 1995-09-29 1998-09-15 Cygnus, Inc. Transdermal administration of ropinirole and analogs thereof
GB9612752D0 (en) * 1996-06-19 1996-08-21 Smithkline Beecham Plc Novel treatment
ATE218548T1 (de) * 1996-08-27 2002-06-15 American Home Prod 4-aminoethoxy-indolon-derivate
ZA992670B (en) * 1998-04-13 2000-10-12 American Home Prod 4-amino-(ethylamino)-oxindole dopamine autoreceptor agonists.
US6176242B1 (en) 1999-04-30 2001-01-23 Medtronic Inc Method of treating manic depression by brain infusion
US6218421B1 (en) * 1999-07-01 2001-04-17 Smithkline Beecham P.L.C. Method of promoting smoking cessation
AR030557A1 (es) 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
US6277875B1 (en) * 2000-07-17 2001-08-21 Andrew J. Holman Use of dopamine D2/D3 receptor agonists to treat fibromyalgia
DE10041478A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
US7858602B2 (en) * 2000-10-16 2010-12-28 Rodriguez Victorio C Therapeutic and prophylactic uses of cell specific carbonic anhydrase enzymes in treating aging disorders due to oxidative stress and as growth factors of stem cells
US6871098B2 (en) * 2000-10-30 2005-03-22 Medtronic, Inc. Method for treating obsessive-compulsive disorder with electrical stimulation of the brain internal capsule
JP4630665B2 (ja) * 2002-09-13 2011-02-09 モタック・ニューロサイエンス・リミテッド ２，３−ベンゾジアゼピンによる基底核関連運動障害の治療
CA2499200A1 (en) * 2002-09-17 2004-04-01 Motac Neuroscience Limited Use of compounds in the treatment of dyskinesia
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10334187A1 (de) * 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
WO2005051488A1 (en) * 2003-11-26 2005-06-09 Pfizer Products Inc. Combination of dopamine agonists and monoamine reuptake inhibitors
DE10361258A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
US7378439B2 (en) * 2004-01-20 2008-05-27 Usv, Ltd. Process for the preparation of 4-(2-dipropylaminoethyl)-1,3-dihydro-2H-indol-2-one hydrochloride
US20050197385A1 (en) * 2004-02-20 2005-09-08 Schwarz Pharma Ag Use of rotigotine for treatment or prevention of dopaminergic neuron loss
DE102004014841B4 (de) * 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
US20090325911A1 (en) * 2005-10-21 2009-12-31 Caritas St. Elizabeth Medical Center Of Boston, Inc. Use of Androgens for the Treatment of Parkinson's Disease
KR101446813B1 (ko) * 2006-04-06 2014-10-01 뉴파쎄 인크. 도파민 연관된 상태의 치료를 위한 이식체
WO2008001204A2 (en) * 2006-06-29 2008-01-03 Antares Pharma Ipl Ag Transdermal compositions of pramipexole having enhanced permeation properties
TW200815045A (en) * 2006-06-29 2008-04-01 Jazz Pharmaceuticals Inc Pharmaceutical compositions of ropinirole and methods of use thereof
US20090247537A1 (en) * 2008-03-25 2009-10-01 William Dale Overfield Methods for preventing or treating bruxism using dopaminergic agents
CN101574341B (zh) * 2008-05-05 2012-12-19 北京德众万全医药科技有限公司 一种罗匹尼罗的口服固体药物组合物
WO2010023693A2 (en) * 2008-09-01 2010-03-04 Lupin Limited Novel controlled release compositions of ropinirole
CA2738414C (en) 2008-09-29 2014-05-27 Wockhardt Research Centre Extended release dosage form of ropinirole
WO2010044108A2 (en) 2008-10-17 2010-04-22 Rubicon Research Private Limited Controlled release formulations of ropinirole
US20100233259A1 (en) * 2008-12-12 2010-09-16 Pascal Grenier Dosage form of ropinirole
JP5820469B2 (ja) 2010-04-30 2015-11-24 テイコク ファーマ ユーエスエー インコーポレーテッド プロピニルアミノインダンの経皮組成物
EP2688561B1 (en) 2011-03-24 2018-08-22 Teikoku Pharma USA, Inc. Transdermal compositions comprising an active agent layer and an active agent conversion layer
EP2776020B1 (en) 2011-11-09 2019-09-11 Teikoku Seiyaku Co., Ltd. Methods for the treatment of skin neoplasms
JP6050896B2 (ja) 2012-11-02 2016-12-21 テイコク ファーマ ユーエスエー インコーポレーテッド プロピニルアミノインダン経皮組成物
US20150313891A1 (en) * 2014-05-02 2015-11-05 Abbvie Inc. Neuronal nicotinic agonists and methods of use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452808A (en) * 1982-12-07 1984-06-05 Smithkline Beckman Corporation 4-Aminoalkyl-2(3H)-indolones
US4588740A (en) * 1982-12-07 1986-05-13 Smithkline Beckman Corporation Pharmaceutical methods using 4-aminoalkyl-2(3H)-indolones

Also Published As

Publication number Publication date
NL970006I2 (nl) 1997-10-01
US4824860A (en) 1989-04-25
NL970006I1 (nl) 1997-04-01
DE3876877T2 (de) 1993-04-29
IE63511B1 (en) 1995-05-03
JPS63303966A (ja) 1988-12-12
DK169609B1 (da) 1994-12-27
JPH062672B2 (ja) 1994-01-12
IE881469L (en) 1988-11-21
CA1305421C (en) 1992-07-21
AU1644588A (en) 1988-11-24
NZ224709A (en) 1997-02-24
AU599792B2 (en) 1990-07-26
LU90098I2 (fr) 1997-09-25
HK1000913A1 (en) 1998-05-08
PT87542A (pt) 1989-05-31
DK275488D0 (da) 1988-05-19
GR3007251T3 (enExample) 1993-07-30
EP0299602B1 (en) 1992-12-23
MX9203543A (es) 1992-07-01
US4912126A (en) 1990-03-27
EP0299602A2 (en) 1989-01-18
DE3876877D1 (de) 1993-02-04
ZA883602B (en) 1989-04-26
HUT47217A (en) 1989-02-28
PH23867A (en) 1989-11-23
GB8712073D0 (en) 1987-06-24
EP0299602A3 (en) 1990-06-06
HU201871B (en) 1991-01-28
DK275488A (da) 1988-11-22
PT87542B (pt) 1992-09-30
ATE83659T1 (de) 1993-01-15

Similar Documents

Publication Publication Date Title
PT87542A (pt) Process for the preparation of a medicament based on indolone derivatives for the treatment of the parkinson disease
ES2150577T3 (es) Aminoeteres aromaticos como agentes para aliviar el dolor.
AR016001A1 (es) Uso de polimeros de amina alifatica para la fabricacion de medicamentos para la reduccion de niveles de oxalato en un paciente
CO4340681A1 (es) Procedimientos de uso para la inhibicion de la perdida osea y la disminucion del colesterol en suero
MX9201730A (es) Nuevos fenilazacicloalcanos substituidos que actuan centralmente.
ES2160640T3 (es) Nuevos (r)-5-carbamoil-8-fluoro-3-amino disustituido en n,n-3,4-dihidro-2h-1-benzopiranos.
NO963053D0 (no) Kosmetiske eller farmasöytiske preparater inneholdende mangiferin eller derivater derav
MX9307885A (es) Aplicacion de la carbamzaepina y oxcarbazepian para la obtencion de medicamentos para el tratamiento de la enfermedad de parkinson y los sindromes parkinsonianos.
FI895520A0 (fi) Anti-aterosklerotiska diaryl foereningar.
ES2108717T3 (es) Derivados de la tetrahidropirrolo(1,2-a)pirazina-4-espiro-3'-pirrolidina, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.
AR016973A1 (es) Uso de aminometil-cromanos sustituidos para la produccion de un medicamento util para el tratamiento de enfermedades neurodegenerativas y para el estimulode la regeneracion neuronal
ES2059534T3 (es) Nuevos derivados benzopiranos antihipertensivos.
ES2058596T3 (es) Empleo de derivados de l-carnitina en el tratamiento terapeutico de alteraciones degenerativas del sistema nervioso.
ES2135342B1 (es) Uso del raloxifeno o una sal o salvato del mismo en la preparacion de un medicamento para prevenir el cancer de mama.
ES2196167T3 (es) Composicion farmaceutica que contiene propionato de 3-(2,2,2-trimetilhidrazinio) y gamma-butirobetaina para el tratamiento de enfermedades cardiovasculares.
CO4230093A1 (es) Derivados del indol y sus usos medicos
PT90308A (pt) Processo para a preparacao de composicoes farmaceuticas contendo azelastina com libertacao controlada da substancia activa
AR012723A1 (es) Derivados triptolidos utiles en el tratamiento de enfermedades autoinmunes y usos en la fabricacion de medicamentos
DK0686155T3 (da) Xanthinderivater som adenosin A1-receptor-antagonister
ES2051986T3 (es) Compuestos con actividad broncodilatadora.
ES2055717T3 (es) Derivados de benzo- y tieno-3,4-dihidro-piridina, procedimientos para su preparacion y medicamentos que contienen estos compuestos.
ES2028871T3 (es) Un procedimiento para la preparacion de un glicosido de antraciclina. .
ATE137490T1 (de) Bizyklische amino-substituierte verbindungen
ES2065855B1 (es) Procedimiento para la preparacion de nuevos derivados desoxiazafosfolipidicos con accion inhibidora de la fosfolipasa a2, nuevos derivados desoxiazafosfolipidicos obtenidos y utilizacion de los mismos.
ES2053683T3 (es) Forma de medicamento de aplicacion oral para el tratamiento de la hipertension una vez al dia con hidrocloruro de diltiazem.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 299602

Country of ref document: ES